Evaluation of Treatment Outcomes of HER-2-Positive Breast Cancer Patients from Provincial General Hospital Dr. M. Djamil Padang
Abstract
Background: Human Epidermal Receptor-2 (HER-2) is a member of the human epidermal growth factor receptor family that can be overexpressed or amplified in 15–20% of breast cancer cases. This overexpression or amplification is associated with excessive proliferation and differentiation resulting in more aggression and shortened disease-free survival (DFS) and overall survival (OS). Treatment strategies rely on several factors, including targeting the specific status of biomarkers like HER-2, one example is Trastuzumab. This study aims to evaluate trastuzumab treatment in HER-2 subtype breast cancer patients who received trastuzumab therapy for 6 months compared to patients who did not receive trastuzumab therapy in terms of DSF and OS from 2017 until 2022.
Methods: This research employed a retrospective descriptive study using secondary data of 126 patients taken from the medical records of the Provincial General Hospital Dr. M. Djamil Padang and the Cancer Registry of the Indonesian Society of Surgical Oncology, Padang. The inclusion criteria for this study were data on breast cancer patients with HER-2 positive who received trastuzumab therapy for 6 months and patients who did not receive trastuzumab therapy. Patients have complete data including name, gender, age, immunohistochemistry results, and their classification can be determined. This study used univariate analysis and Kaplan-Meier for survival analysis methods.
Results: The results of this study showed that the highest age group was over 50 years, the most common histopathological subtype was invasive Carcinoma Mammae of NST (Non-Special Type), and the most frequent TNM stage was Stage II. Patients who received 6 months of trastuzumab therapy had disease-free survival of 46 months (95% CI 39.95–51.15) and an overall survival of 53 months (95% CI 49.19–57.24). In the early stage, the disease-free survival rate was 56 months (95% CI 38.89–56.60), while in a locally advanced stage, the disease-free survival rate was 39 months (95% CI 51.52–61.21).
Conclusions: There was a prolongation of disease-free survival and overall survival rates when trastuzumab therapy was given for 6 months. The prognosis of HER-2-positive breast cancer patients in the early stage was better than patients in the locally advanced stage.
Keywords
DOI: 10.33371/ijoc.v18i4.1176
Article Metrics
Abstract View: 179, 
PDF Download: 65
References
WHO. Breast cancer 2021. https://www.who.int/news-room/fact-sheets/detail/breast-cancer (accessed February 22, 2022).
The Global Cancer Observatory. Cancer Incident in Indonesia. Int Agency Res Cancer 2020;858:1–2.
Ayuza M, Harahap WA, Rustam R, Nindrea RD. Faktor yang Berpengaruh Terhadap Disease Free Survival dan Overall Survival pada Pasien Kanker Payudara Usia Muda di Kota Padang Tahun 2008 - 2018. J Kesehat Andalas 2020;9:65–73.
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 2018;5:77.
Frank GA, Danilova N V., Andreeva YY, Nefedova NA. WHO Classification of tumors of the breast, 2012. Arkh Patol 2013;75:53–63.
Abubakar M, Guo C, Koka H, Sung H, Shao N, Guida J, et al. Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression. Npj Breast Cancer 2019 51 2019;5:1–9.
Al-thoubaity FK. Molecular classification of breast cancer: A retrospective cohort study. Ann Med Surg 2020;49:44–8.
Harahap WA, Ramadhan, Khambri D, Haryono S, Nindrea RD. Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer. Asian Pac J Cancer Prev 2017;18:1151–6.
Nassar A, Khoor A, Radhakrishnan R, Radhakrishnan A, Cohen C. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas. Int J Clin Exp Pathol 2014;7:6254.
Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int 2014;2014:1–9.
Zheng K, Tan JX, Li F, Li HY, Zeng XH, Ma BL, et al. Clinicopathologic Factors Related to the Histological Tumor Grade of Breast Cancer in Western China: An Epidemiological Multicenter Study of 8619 Female Patients. Transl Oncol 2018;11:1023.
Prawirohardjo S. Ilmu Kebidanan. Edisi ke 4. Jakarta: Bina Pustaka Sarwono; 2016.
Camejo N, Castillo C, Alonso R, Correa F, Rivero E, Mezquita C, et al. Effectiveness of Trastuzumab for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in a Real-Life Setting: One Decade of Experience Under National Treatment Coverage Regulations. JCO Glob Oncol 2020;6:217–23.
Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008;107:309–30.
Abi Jaoude J, Kayali M, de Azambuja E, Makki M, Tamim H, Tfayli A, et al. De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost? Int J Radiat Oncol Biol Phys 2020;108:1040–6.
Harahap WA, Ramadhan, Khambri D, Haryono S, Nindrea RD. Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer. Asian Pac J Cancer Prev 2017;18:1151–6.
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, De Azambuja E, Procter M, Suter TM, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (London, England)
Findlay VJ, Scholar E. Trastuzumab. XPharm Compr Pharmacol Ref 2021:1–5.
Boekhout AH, Beijnen JH, Schellens JHM. Trastuzumab. Oncologist 2011;16:800.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
